|
Kronos Bio, Inc. (KRON): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Kronos Bio, Inc. (KRON) Bundle
In the cutting-edge world of precision oncology, Kronos Bio, Inc. (KRON) emerges as a pioneering biopharmaceutical company targeting the complex landscape of cancer treatment. With a laser-focused approach on developing innovative targeted therapies, particularly their breakthrough menin inhibitor KO-539 for MLL-rearranged leukemia, Kronos Bio is redefining the boundaries of molecular targeted therapeutics. Dive into this comprehensive marketing mix analysis to uncover how this South San Francisco-based innovator is strategically positioning itself to transform cancer care and potentially revolutionize treatment options for patients battling serious diseases.
Kronos Bio, Inc. (KRON) - Marketing Mix: Product
Biopharmaceutical Company Overview
Kronos Bio, Inc. is a precision oncology company developing targeted therapies for cancer and serious diseases.
Product Pipeline
| Drug Candidate | Indication | Development Stage |
|---|---|---|
| KO-539 | MLL-rearranged Leukemia | Phase 1/2 Clinical Trial |
| KB-0742 | Solid Tumors | Preclinical Development |
Key Product Characteristics
- Specialized in molecular targeted therapeutics
- Focus on precision oncology treatments
- Developing small molecule inhibitors
Research and Development Focus
Primary Research Areas:
- Menin inhibitor development
- Acute myeloid leukemia (AML) treatment
- Precision oncology therapeutics
Product Development Metrics
| Metric | Value |
|---|---|
| R&D Expenses (2023) | $89.4 million |
| Clinical Trial Investments | $62.1 million |
Product Technology Platform
Focused on developing novel small molecule therapeutics targeting specific molecular pathways in cancer treatment.
Kronos Bio, Inc. (KRON) - Marketing Mix: Place
Headquarters Location
333 Oyster Point Boulevard, South San Francisco, California 94080, United States
Global Research and Development Operations
| Location Type | Specific Details |
|---|---|
| Primary Research Facility | South San Francisco, California |
| Clinical Trial Centers | Multiple research centers across United States |
Clinical Trial Locations
- MD Anderson Cancer Center, Houston, Texas
- Memorial Sloan Kettering Cancer Center, New York
- Dana-Farber Cancer Institute, Boston, Massachusetts
Institutional Collaborations
| Collaboration Type | Partner Institutions |
|---|---|
| Academic Research | Stanford University |
| Medical Research Centers | University of California, San Francisco |
Distribution Channels
- Specialized oncology treatment centers
- Academic medical research facilities
- Targeted pharmaceutical distribution networks
Market Access Potential
Potential Market Reach: Approximately 1,500 specialized oncology treatment centers in the United States
Kronos Bio, Inc. (KRON) - Marketing Mix: Promotion
Investor Presentations and Scientific Conference Participation
Kronos Bio participated in the following key investor and scientific events in 2023:
| Conference | Date | Type of Presentation |
|---|---|---|
| H.C. Wainwright Global Investment Conference | September 12, 2023 | Corporate Presentation |
| Cantor Fitzgerald Healthcare Conference | October 4, 2023 | Investor Presentation |
| American Society of Hematology Annual Meeting | December 9-12, 2023 | Scientific Research Presentation |
Peer-Reviewed Publications
Kronos Bio published research in the following peer-reviewed journals in 2023:
- Blood Journal: Published data on KRON-120 clinical trial results
- Nature Cancer: Presented molecular mechanism research
- Journal of Clinical Oncology: Shared phase 1/2 clinical trial findings
Digital Marketing Channels
Digital marketing metrics for Kronos Bio in 2023:
| Platform | Followers/Visitors | Engagement Rate |
|---|---|---|
| Company Website | 47,500 monthly visitors | 3.2% |
| 8,750 followers | 2.7% | |
| 5,400 followers | 1.9% |
Healthcare Professional Engagement
Engagement strategies with oncology research communities:
- Direct outreach to 350+ oncology research centers
- Sponsored 12 medical education workshops
- Conducted 45 targeted webinars for healthcare professionals
Clinical Trial Communication
Communication milestones for drug development in 2023:
| Drug Candidate | Clinical Stage | Press Releases |
|---|---|---|
| KRON-120 | Phase 2 | 6 detailed press releases |
| KRON-240 | Phase 1 | 4 progress updates |
Kronos Bio, Inc. (KRON) - Marketing Mix: Price
Company Stock and Financial Overview
As of January 2024, Kronos Bio, Inc. (NASDAQ: KRON) trading price ranges between $3.50 - $4.25 per share. Market capitalization approximately $178 million.
| Financial Metric | Value |
|---|---|
| Stock Price (January 2024) | $3.87 |
| Market Cap | $178 million |
| 52-Week Low | $2.76 |
| 52-Week High | $5.64 |
Pricing Strategy for Oncology Treatments
Research and development focused company with potential pricing strategy for precision oncology treatments.
- Primary development focus: Precision oncology therapies
- Clinical-stage biotechnology company
- No current commercial product revenue
Financial Performance Indicators
| Financial Metric | 2023 Value |
|---|---|
| R&D Expenses | $89.4 million |
| Net Loss | $103.2 million |
| Cash and Equivalents | $211.6 million |
Potential Pricing Considerations
Pricing strategy contingent on:
- Clinical trial outcomes
- Breakthrough therapy designation
- Potential market effectiveness
- Competitive landscape in precision oncology
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.